Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Rating of “Hold” from Analysts

Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) have been assigned a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $78.5556.

A number of research analysts have commented on the company. Weiss Ratings cut Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Benchmark lifted their price objective on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, February 19th. TD Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Wall Street Zen cut Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, HC Wainwright reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $63.43 on Friday. Halozyme Therapeutics has a 1-year low of $47.50 and a 1-year high of $82.22. The stock has a market cap of $7.49 billion, a PE ratio of 25.47, a P/E/G ratio of 0.26 and a beta of 0.98. The firm has a 50-day simple moving average of $71.53 and a two-hundred day simple moving average of $70.22. The company has a debt-to-equity ratio of 43.89, a current ratio of 4.66 and a quick ratio of 3.66.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million during the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The business’s revenue was up 51.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.26 earnings per share. As a group, analysts forecast that Halozyme Therapeutics will post 4.73 EPS for the current year.

Insider Activity at Halozyme Therapeutics

In related news, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the sale, the chief executive officer directly owned 708,719 shares of the company’s stock, valued at $53,947,690.28. This represents a 2.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $70.25, for a total transaction of $140,500.00. Following the sale, the director owned 40,123 shares in the company, valued at approximately $2,818,640.75. This trade represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 90,857 shares of company stock worth $6,500,287. Corporate insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Root Financial Partners LLC acquired a new position in Halozyme Therapeutics during the 3rd quarter worth $25,000. Measured Wealth Private Client Group LLC raised its position in Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares in the last quarter. Larson Financial Group LLC boosted its stake in shares of Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares during the period. Richardson Financial Services Inc. grew its position in shares of Halozyme Therapeutics by 87.6% during the third quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 198 shares in the last quarter. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Halozyme Therapeutics during the second quarter worth about $32,000. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.